Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.

Ingegnoli, F; Fantini, F; Griffini, S; Soldi, A; Meroni, P L; Cugno, M

Ingegnoli, F; Fantini, F; Griffini, S; Soldi, A; Meroni, P L; Cugno, M.

Affiliation

Ingegnoli F; Department of Rheumatology, University of Milan, Istituto Gaetano Pini, Milan, Italy.

Clin Exp Rheumatol ; 28(2): 254-7, 2010.

Article in En | MEDLINE | ID: mdl-20483049

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Fibrinolysis/drug effects; Thrombosis/drug therapy; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Adult; Arthritis, Rheumatoid/epidemiology; Arthritis, Rheumatoid/immunology; Atherosclerosis/epidemiology; Biomarkers/blood; Drug Therapy, Combination; Female; Fibrinolysis/immunology; Humans; Infliximab; Male; Methotrexate/therapeutic use; Middle Aged; Risk Factors; Thrombosis/epidemiology; Thrombosis/immunology; Young Adult

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Arthritis, Rheumatoid / Thrombosis / Tumor Necrosis Factor-alpha / Antirheumatic Agents / Fibrinolysis / Antibodies, Monoclonal Type of study: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2010 Type: Article

Search on Google

XML

PubMed Links